Mitotic cells typically lack well-formed focal adhesions. As an approach to explore the dynamic process regulating the focal adhesion assembly, we examined states of focal adhesion proteins during mitosis of the cell cycle. We found that the amount of paxillin was signi®cantly reduced during mitosis of the cell cycle, whereas other focal adhesion proteins including talin, vinculin and Focal Adhesion Kinase did not. Proteolytic degradation appeared to be involved in the mitotic reduction, but transcriptional and/or translational controls of the mRNA were not essential for this downregulation. Moreover, concurrent with the decreased protein level, phosphorylation status of paxillin altered during mitosis; mitotic paxillin was phosphorylated primarily on serine and dephosphorylated on tyrosine while interphase one was phosphorylated both on serine and tyrosine. We found that mitotic phosphorylation created an electrophoretically slow-migrating population of paxillin which was barely detected in interphase cells. This mitotic speci®c modi®cation occurred with both a and b isoforms of paxillin. We also examined the fate of paxillin protein by changing its protein amount. We found that majority of paxillin overexpressed was subjected to the speci®c modi®cation but not to the downregulation in the mitotic arrested cells. On the other hand, paxillin exogenously expressed at a moderate level was subjected to both the mitotic modi®cation and downregulation. Collectively, we concluded that paxillin's speci®c serine phosphorylation together with the proteolytic downregulation of a limited fraction of paxillin is taken place during the mitosis of the cell cycle.
Introduction
Integrins mediates cell adhesion to extracellular matrices and to other cells and involve in the regulation of cell motility, growth, dierentiation and survival (for reviews see Hynes, 1992; Juliano and Haskill, 1993; Meredith et al., 1993; Frisch and Francis, 1994) . Integrins themselves have no intrinsic enzymatic activity and appears to function by interacting with a number of other proteins (for a review see Clark and Brugge, 1995) . Integrin aggregation upon their binding to the substratum, which accompanies an assembly of several proteins at or near the cytoplasmic domain of the integrin, forms a distinct structure, a focal adhesion assembly; which then lead to the organization of the actin-containing cytoskeleton. Moreover, to mediate dynamic cellular functions of integrins, a dynamic nature also have to be required for the regulation of the focal adhesion assembly.
Focal complex assembly is absent in cells kept in suspension, or in a certain types of serum-starved cells or cells at con¯uent density (Ridley and Hall, 1992) . Formation of the focal adhesion assembly can be induced by cell adhesions to the ECM even in the absence of serum or mitogens, and tyrosine phosphorylation of focal adhesion proteins including Focal Adhesion Kinase (Fak), paxillin and tensin is necessary in this process (Burridge et al., 1992) , which then induces the src homology 2 domain mediated proteinprotein bindings. On the other hand, stimulation of the serum-starved adherent Swiss 3T3 ®broblast cells with mitogens can also induce a rapid formation of the focal adhesion complex and small GTP binding protein Rho has been shown to play a critical role in this process (Ridley and Hall, 1992) . Moreover, among the many focal adhesion proteins, it has been shown that there is a hierarchy in the orders of the protein assemblies with the cytoplasmic domains of the activated integrin (Miyamoto et al., 1995a,b) . The reversed process, however, that regulates the process of the focal adhesion disassembly is not well studied.
Most cultured adherent cells become rounded-up and a few focal contacts are seen during the mitosis. It is reported in nocodazole-arrested Chinese hamster ovary (CHO) cells that functional ®bronectin receptors are expressed on the cell surface with little change in either their number or ligand anity, indicating that rounding up of the cells during mitosis and disappearance of the focal adhesions are not simply due to the reduced anity of integrin per se for the extracellular ligand (Pomies and Block, 1992) . Thus factor(s) regulating the assembly of proteins at the cytoplasmic regions of integrins may be altered during mitosis, to disassemble the focal assembly. We thus examined states of focal adhesion proteins during mitosis. We have previously observed that the amount of focal adhesion protein, paxillin, is decreased in nocodazole-arrested NIH3T3 ®broblasts . We here report a signi®cant decrease in the protein level of paxillin, but not other focal adhesion proteins, in several dierent types of mitotic cells with or without the use of microtubule-polymerization inhibitors. Our data indicated that the proteolytic degradation appears to be the major reason for this downregulation. Our results also pointed out that only a limited amount of paxillin could be degraded during mitosis. Accompanying the decreased protein level, phosphorylation status of paxillin was also changed in mitotic arrested cells. We found that mitotic paxillin is primarily phosphorylated on serine concurrent with dephosphorylation on tyrosine, while interphase paxillin is phosphorylated both on serine and tyrosine. This mitotic serine phosphorylation causes speci®c retardation of a fraction of paxillin when separated on SDS ± PAGE, and disappeared upon cell's exit from the mitosis. The altered phosphorylation of mitotic paxillin may relate with the disassembly of the focal complexes and/or its proteolytic degradation, which may also then cause disorganization of the focal assembly.
Results

Reduced protein level of paxillin in mitotic cells
We ®rst examined the amounts of focal adhesion proteins in cells arrested at mitosis using nocodazole. In Figure 1a , the representative results using rat 3Y1 ®broblasts are shown. The amount of paxillin, measured by immunoblotting, was signi®cantly decreased in the nocodazole arrested mitotic cells. Cells treated with nocodazole but not entered mitosis and remained adhered onto culture dishes showed much the same amount of paxillin as in the exponentially growing cells (Figure 1a ). These results with 3Y1 cells are consistent with our previous observation with nocodazole-arrested mouse NIH3T3 cells ; also see Figure 6 ). Blotting the same ®lter with a dierent clone of a monoclonal anti-paxillin antibody or polyclonal anti-paxillin antibody yielded similar results (data not shown), indicating that possible mitotic-speci®c modi®cation of paxillin at or near sites of the epitope recognition is unlikely to be responsible for the reduced detection. Such a reduction during mitosis was not observed with other focal adhesion proteins including talin, tensin, vinculin, Fak (Figure 1b) , b-actin and integrin b1 (data not shown).
We then examined a variety types of cells, including HeLa epithelial cells, CHO ®broblast, Jurkat lymphocytes ( Figure 2a ) and Cos 7 cells (see Figure 6c) , arrested at the mitosis by the treatment with nocodazole. With CHO cells, naturally mitotic cells were also collected by gentle mechanical shaking o the exponentially growing population. HeLa cells once synchronized at the G1/S phase of the cell cycle by a double thymidine block method, and then released and entered into the next mitotic phase were also collected. In all of these preparations, a signi®cant reduction in the amount of paxillin during the mitotic phase of the cell cycle was observed (Figure 2a ). We also used another microtubule-polymerization inhibitor demecolcine to arrest cells at mitosis, and obtained the similar results (data not shown). On the other hand, the level of paxillin mRNA did not change during the mitotic arrest as compared with that in exponential growing cells (Figure 2b) .
A fraction of paxillin in exponential growing cells are phosphorylated both on serine and tyrosine (Glenney and Zokas, 1989 ; also see Figure 5b ), and thereby exhibits multiple protein bands when separated on SDS ± PAGE. Expression of paxillin isoforms of a and b in HeLa cells and ®broblastic cells also contributes to the multiplicity of the bands (Mazaki et al., 1997; our unpublished data) . We found that a very slow-migrating fraction(s) of paxillin on SDS ± PAGE, that was barely detected in interphase, exponentially growing phase and naturally mitotic cells, was clearly detected in these mitotic arrested cells (Figure 2 ). Such a retarded fraction was also detected with 3Y1 cells (data not shown) and NIH3T3 cells (see Figure 6a and b) when the immunoblots were exposed for a longer time.
We next investigated whether a reduction in the amount of paxillin as well as an appearance of the very slow-migrating form are events speci®c to mitosis, or is a result of the altered cellular environment during the mitosis or the nocodazole-induced mitotic arrest. We have shown that merely keeping cells in suspension for up to 10 h does not cause signi®cant reduction of paxillin protein (Yamaguchi et al., 1994) . We then considered whether detachment of cells from culture environment in combination with a disruption of the microtubule network could be a cause of the paxillin alteration. Exponentially growing cells were trypsinized and suspended in the culture medium in the presence of nocodazole. Neither changes in the amount of paxillin nor appearance of slower migrating forms was detected in CHO cells treated as above (Figure 2c ). Same result was obtained with other types of adherent cells (data not shown). Thus, it is unlikely that the alteration of paxillin we observed in the mitotic arrested cells is due merely to the combined eects of nocodazole treatment and rounded-up morphology of cells.
Reduced protein stability of paxillin during mitosis
Apparent stability of paxillin protein was then examined by treating cells with cyclohexamide. The apparent half-life of paxillin in cells arrested at mitosis with nocodazole was signi®cantly less (T 53 ± 6 h) than its apparent half-life in interphase cells (T 46 h) ( Figure 3 ). We also examined the stability of other proteins. Proteins such as vinculin (Figure 3) , b-actin, talin and tensin (data not shown) exhibit half-lives of longer than 6 h in the mitotic arrested cells. HeLa cells arrested at mitosis with nocodazole do not reach the metaphase, and thus most cyclin B1 protein remained undegraded ( Figures 3b and 4) . Interestingly, the apparent half-life of cyclin B1 protein, measured in the presence of cyclohexamide in nocodazole-arrested mitotic HeLa cells, was much the same as that of paxillin ( Figure 3b ). These results indicated that the shortened half-life or the apparent loss of protein stability in the mitotic arrested cells in not universal to most proteins, but may rather be a speci®c event for 0 hr 1.5 hr 3 hr 6 hr 0 hr 1.5 hr 3 hr 6 hr 0 hr 1.5 hr 3 hr 6 hr n.d. Figure 3 Decreased apparent half-life of paxillin during the mitotic arrest. HeLa cells at the exponential growing (a) nocodazolearrested mitosis (b) and nocodazole-arrested mitosis and then added with 10 mM MG132 (c) were treated with 100 mg/ml of cyclohexamide for the indicated length of time. Cell lysates were then prepared and subjected to immunoblotting using antibodies against vinculin (upper panels), paxillin (middle panels) and cyclin B1 (lower panels) certain types of proteins including paxillin and cyclin B1, a mitotic cyclin.
MG132 restored apparent half-life of paxillin in nocodazole-arrested cells
To obtain further evidence supporting that the apparent instability of paxillin protein during mitosis is due to the protein degradation, we treated cells with a peptide aldehyde MG132. Rock et al., 1994) that can inhibit selectively the bulk of intracellular proteolysis activities including those of the 20S and 26S proteasomes, calpains and lysosomal cysteine proteases, for several hours without obvious toxicity to the cells or aecting the rates of protein synthesis (Rock et al., 1994; Palmbella et al., 1994; Goldberg, 1995) . In HeLa cells, a shorter half-life of paxillin was overcome by the treatment of mitotic cells with MG132, along with the similar stabilization of cyclin B1 protein ( Figure 3c ). Same eect was also con®rmed with nocodazole-arrested other types of adherent cells (data not shown).
Concurrent with the decreased protein level, a fraction of mitotic paxillin shows slow migration on SDS ± PAGE and is serine phosphorylated
In addition to the reduced protein levels, we observed that a signi®cant fraction of mitotic paxillin migrated very slowly on SDS ± PAGE, as already mentioned (see Figure 2a , also see Figure 6 ). We next checked whether the appearance of the slow-migrating forms of paxillin correlates with the mitosis. Mitotic arrested cells were washed free of nocodazole, then plated onto fibronectin pre-coated culture dishes in the presence of serum, to be progressed into next G1 phase of the cell cycle. As shown in Figure 4 , the disappearance of the slowmigrating species of paxillin was seen within 1 ± 2 h after plating the mitotic arrested cells, and this timing was well correlated with the disappearance of cyclin B1 protein. Again, the same was con®rmed with other types of adherent cells (data not shown).
To examine the possible modi®cation of mitotic paxillin, we next treated mitotic cell lysates with bacterial alkaline phosphatase (BAP). We found that BAP treatment restored the electrophoretical mobility of mitotic paxillin (Figure 5a ). Moreover, in contrast to paxillin in exponential growing cells which was phosphorylated both on serine and tyrosine, mitotic paxillin was phosphorylated primarily on serine and its tyrosine residue(s) was dephosphorylated (Figure 5b ). These results indicate that the mitotic speci®c hyperretardation of paxillin is primarily due to its serine phosphorylation. It is also noteworthy that BAP treatment did not result in an increased level of mitotic paxillin cross-reacting with anti-paxillin antibodies (Figure 5a ; data not shown). This again argues against the possibility that mitotic-speci®c modi®cation of paxillin hinders the epitope recognition. These results were also con®rmed with other types of adherent cells (data not shown).
Both a and b isoforms of paxillin are subjected to the mitotic alteration
We have identi®ed two novel isoforms of paxillin with dierent molecular sizes (paxillin b and g; we call previously reported paxillin as a isoform) (Mazaki et al., 1997) . We also found that mouse ®broblasts such as NIH3T3 cells express both a and b isoforms with a ratio comparable to each other (our unpublished data). We therefore examined whether the hyper-retarded band(s) seen in the mitotic arrested cells may be a modi®cation of a speci®c isoform of paxillin. As shown in Figure 6a , both isoforms overexpressed in NIH3T3 cells by the infection of the recombinant retroviruses showed retarded mobilities when the cells were arrested at the mitosis by nocodazole treatment. A fraction of endogenous paxillin also showed similar retardation in its motility in the mitotic arrested cells (Figure 6a ; also see Figure 6b ). These retardations also could be restored by the treatment with alkaline phosphatase (data not shown), same as shown in Figure 5 . Again, with cells that were treated with nocodazole but remained adherent interphase of the cell cycle, both isoforms of paxillin showed the same motility as in the exponentially growing cells (Figure 6a ).
Limited downregulation in the protein level of paxillin in mitotic arrested cells
In contrast to the endogenous paxillin, no signi®cant reductions in the amounts of the overexpressed isoforms of a and b were observed in the mitotic arrested cells (Figure 6a ). Paxillin isoform cDNAs in the retrovirus vector are transcribed from the murine retrovirus long terminal repeat promoter and do not contain the 5'-as well as the 3'-untranslated regions of paxillin mRNAs (Mazaki et al., 1997) ; thus endogenous transcriptional regulation of paxillin mRNA, if any, may not be applied and the mRNAs transcribed from the retrovirus vector may escape from the possible intrinsic regulation of the endogenous paxillin mRNA. Or, alternatively, since the protein levels of the paxillin isoforms expressed exogenously were 10 ± 20-fold higher than those of endogenous ones, as assessed by the densitometric analysis of the immunoblots (data not shown; see Figure 6a ), it is simply because the amounts of the overexpressed paxillin proteins are far above the permissible amounts of the mitotic degradation. To test these possibilities, we used other constructs of paxillin cDNAs. We found that a recombinant retrovirus bearing Green Fluorescence Protein (GFP) fused paxillin sequence expressed much the same amount of the protein as that of the endogenous paxillin (Figure 6b ). This retrovirus vector construct also does not contain the 5'-and 3'-untranslated regions of paxillin mRNA. With GFPfusion forms of paxillin isoform a (94 kDa in a molecular size) and isoform b (95 kD in a molecular size), we found that protein levels were indeed reduced signi®cantly in the mitotic arrested cells, together with the appearance of the mitotic speci®c slow-migrating forms (Figure 6b ). Of note, the endogenous paxillin, which is now clearly distinguishable from the exogenous one, showed same alteration in the same cell population (Figure 6b ). We have also con®rmed that the GFP-paxillins are indeed localized to the focal adhesions (our unpublished observation). Moreover, GFP protein itself did not show such an alteration though the endogenous paxillin in the GFP transfected cells again showed the mitotic alteration (Figure 6c ). Therefore, together with our results shown in the previous ®gures we concluded that only a limited amount of paxillin is downregulated by its proteolytic degradation during the mitosis. Possible transcriptional and/or translational controls of paxillin mRNAs may not be essential for the mitotic downregulation.
Discussion
We present evidences that a protein level of paxillin is speci®cally reduced by its proteolytic degradation during mitosis. We also showed that a fraction of paxillin is subjected to the mitotic speci®c serine phosphorylation accompanied with dephosphorylation on tyrosine residue(s). Paxillin was originally identi®ed as one of the major cellular substrate of the v-Src tyrosine kinase (Glenney and Zokas, 1989) . Biochemical analysis has revealed that paxillin appears to be important in connecting the integrin with actin-stress ®ber, via interacting with vinculin, talin and the cytoplasmic domain of integrin b1; paxillin also interact with signal transducers such as Fak and c- Figure 6 Fates of exogenously expressed paxillin in the mitotic arrest cells. (a and b) NIH3T3 cells were infected with recombinant retroviruses bearing pBabePuro vector (a, lanes 1 ± 3), pBabePuro/human paxillin a (a, lanes 4 ± 6), pBabePuro/human paxillin b (a, lanes 7 ± 9), pBabePuro/GFP-paxillin a (b, lanes 1 ± 3) and pBabePuro/GFP-paxillin b (b, lanes 4 ± 6). Cell lysates (5mg in each lane) were then prepared from exponential growing (lanes 1, 4 and 7), nocodazole treated interphase (lanes 2, 5 and 8) and nocodazolearrested mitotic (lanes 3, 6 and 9) cells as indicated, separated on SDS ± PAGE and subjected to immunoblotting using polyclonal anti-paxillin Ab (upper panels in a and b), and anti-vinculin Ab (lower panels in a and b). The exposure times of upper panels of a and b were 1 min and 5 min, respectively. (c) Cos 7 cells were transfected with pBabePuro/GFP DNA, and 32 h after the transfection cells were either subjected to nocodazole treatment (40 ng/ml for 16 h, lane 2) or left untreated (lane 1). Cell lysates were then prepared and subjected to immunoblotting analysis using anti-GFP Ab (upper panel), anti-paxillin Ab (middle panel) and anti-vinculin Ab (lower panel)
Src (Turner et al., 1990; Weng et al., 1993; Wood et al., 1994; Turner and Miller, 1994; Salgia et al., 1995; Hildebrand et al., 1995; Tachibana et al., 1995; Tanaka et al., 1996) . Thus, changes in the protein level of paxillin may contribute to the changes in the organization of focal adhesion assemblies during the mitosis of the cell cycle. Moreover, tyrosine phosphorylation of paxillin creates binding sites for the src homology 2 (SH2) domains of a protein tyrosine kinase Csk and a SH2/SH3 adaptor protein Crk Sabe et al., 1995) . Tyrosine dephosphorylation of paxillin during the mitosis also relates to the changes in the binding of paxillin to its cognate neighbors bearing the SH2 domains.
In natural mitotic CHO cells we observed about 40 ± 60% reduction of paxillin in repeated experiments. With cell lines other than CHO cells it was quite dicult to collect a biochemical amount of natural mitotic cells. In HeLa cells that were pre-synchronized at G1/S phase of the cell cycle by a method of double thymidine block and then released into mitosis, we also observed a large reduction of paxillin. In mitotic arrested cells, amounts of paxillin were also signi®cantly reduced. However, our data indicate that not all endogenous paxillin may be degraded during mitosis. We also showed that majority of paxillin proteins when overexpressed exogenously are not subjected to the mitotic downregulation, while paxillin expressed exogenously at moderate levels are mitotically downregulated. Thus, there appears to be a limitation in the amount of proteolytic decrement of paxillin during mitosis. Such a proteolysis of a limited fraction of proteins during mitosis is also seen with yeast Cut 2 protein, for example, which is essential for the mitotic progression (Funabiki et al., 1996) . The proteolysis machinery may degrade only a fraction of paxillin by targeting a certain subpopulation of the protein during the mitosis.
The degrees of the reduction of paxillin protein in mitotically arrested cells were varied among dierent cell lines we have used (40 ± 60% reduction and 40 ± 70% reduction in the case of CHO and NIH3T3 cells, respectively, in our repeated experiments; and almost disappearance in 3Y1 cell). The regulatory machinery of mitosis progression may not be the same among these dierent cell lines. For example, there are considerable dierences between CHO and HeLa cells regarding the timing of cyclin B synthesis and Cdc2/cyclin B complex formation: in CHO cells Cdc2/cyclin B complex is already prevalent in S phase of the cell cycle, while the complex is barely detectable in S phase of HeLa cells (Steinmann et al., 1991) . We have also observed that MG132 can arrest CHO cells at the stage of the metaphase/ anaphase transition, while the drug cannot render such an eect on HeLa cells (our unpublished observation). These dierences may thereby give rise to dierent eects on the timing and the degree of the paxillin degradation during the mitosis. Moreover, it is inevitable to incubate cells with microtuble inhibitors for a relatively long time to collect a biochemical amount of cells, and this long incubation may also aect paxillin degradation dierently among dierent cell lines we have used.
We used inhibitors of microtuble-polymerization to arrest cells at the mitosis; these inhibitors arrest cells during the prophase. These our analysis thus could not determine whether the degradation of paxillin takes place at a restricted stage during the mitosis, or occurs rather continuously during the entire stages of the mitosis. Our analysis also could not exclude a possibility that paxillin degradation is initiated even during the G2 phase or the G2/M transition of the cell cycle. In this regard, it may be noteworthy that in CHO cells the amount of paxillin in natural mitotic cells is much less than that in the nocodazole-arrested cells (Figure 2) . The same was also seen with HeLa cells as comparing mitotic cells of the pre-synchronized population with nocodazole-arrested cells (Figure 2) . Natural mitotic cells seem to be more rounded-up and become easier to be shaken o from the culture dish during or after the metaphase. Moreover, we have observed in CHO cells arrested at the anaphase/ metaphase transition by MG132 treatment that an amount of paxillin protein was also signi®cantly reduced as compared with that in the exponential growing cells (our unpublished data). These data collectively suggest that the paxillin downregulation is initiated before or during the prophase and continue even after the prophase.
Accompanying the reduced amount of paxillin, we also observed the appearance of very slower-migrating fraction of paxillin on SDS ± PAGE in mitotically arrested cells. Again, the amount of the slowmigrating paxillin also vary, depending on cell types. We showed that the slow-migrating form of paxillin disappears upon exit from the mitosis, and serine phosphorylation is the major reason for this retarded migration. Therefore, the mitotic speci®c serine phosphorylation is taken place with paxillin, and this form may be dephosphorylated or selectively proteolysed upon the cell cycle progression into next G1 phase.
Another mitotic alteration regarding the phosphorylation status of paxillin is dephosphorylation on its tyrosine residue(s). Cell to substratum adhesion evokes tyrosine phosphorylation of a fraction of paxillin (Burridge et al., 1992) , and the tyrosine dephosphorylation may be simply due to the loose cell substratum adhesion in mitotic cell. It is, however, also possible that the tyrosine dephosphorylation may precede the cell cycle progression into mitosis and cause the disassembly of the focal adhesions.
The majority of the overexpressed paxillin was subjected to the mitosis speci®c phosphorylation in the mitotic arrested cells. Our observation of the localization of GFP-paxillin by its¯uorescence and endogenous as well as exogenous paxillin by the immunostaining, has revealed that a signi®cant fraction of them are indeed localized to the focal adhesions (our unpublished data). However, subpopulations of endogenous paxillin as well as GFP-paxillin, that is expressed at a level comparable to the endogenous paxillin, are also detected at the perinuclear regions and the cytoplasm; and with paxillin overexpressed, majorities are detected there (our unpublished observation). Therefore, paxillin seems to be subjected to the mitotic phosphorylation, even if it is not localized to the focal adhesions.
The mitotic speci®c phosphorylation has been observed with a number of proteins that regulate the cytoskeletal as well as nuclear structure. There is general consensus with regard to the nuclear envelope proteins, for example, that the mitotic speci®c phosphorylation causes a detachment from their neighbors thereby contributing to the nuclear breakdown at mitosis (for reviews see Nigg, 1993; Moir et al., 1995; Simos and Georgatos, 1992; Pfaller and Newport, 1995) . The cyclin B-dependent mitotic kinase, Cdc2, is shown to be directly responsible for these phosphorylation events (for review see Nigg, 1993) , together with the contribution of other kinases (Simos and Georgatos, 1992; Pfaller and Newport, 1995) . The primary structure of paxillin contains a consensus phosphorylation sequence for the Cdc2 kinase, and paxillin can be a substrate for the kinase in vitro (our unpublished data). It is also possible that the serine phosphorylated form may be a intermediate for the proteolytic degradation, as has been shown with IkB and p105 which are then subjected to the ubiquitin-mediated rapid degradation by proteasomes (Ghosh and Baltimore, 1990; Palombella et al., 1994; Brown et al., 1995; Chen et al., 1995; Miyamoto et al., 1994) . This assumption may be able to interpret why the mitotic speci®c serine phosphorylated form is more clearly detected in the prophase arrested cells than in the natural miotic cells. It is also noteworthy that the apparent shorter half-life of paxillin during mitosis can be overcome by incubation with MG132, which is a very potent inhibitor of 20S and 26S proteasome activity. We are currently determining the mitotic speci®c phosphorylation site(s) together with identifying the responsible kinase(s), and examining the relation of the mitotic serine phosphorylation of paxillin and its downregulation.
This study was orginally initiated with the aim of understanding the focal adhesion dynamics in adhesive cells. It will be then the matter of our consideration how much this mitotic alteration of paxillin is contributing to the regulation of the focal adhesion assembly and disassembly. It is reported recently that papillomavirus E6 oncoprotein bind to paxillin and this binding appears to lead to the disruption of actin ®ber formation (Tong and Howley, 1997) , indicating the important role of paxillin in the maintenance of the integrity of actin cytoskeletal network. It has also been reported that only about 4% of cellular paxillin localizes to the perimembrane fraction in human neutrophils (Fuortes et al., 1994) , and we have also observed degradation of paxillin in nonadherent lymphocytes. In addition to its role in integrinmediated focal adhesions or cell to cell adhesions, paxillin may have other yet unknown functions such as in cytoskeletal organization and cell cycle progression. Moreover, this system will also provide us a way to understand how the nuclear program of the mitotic progression interacts with the regulatory mechanism in the focal adhesions.
Materials and methods
Antibodies
The following antibodies were purchased from Sigma Chemical Co. (St Louis, MO); anti-b-actin monoclonal antibody (mAb) (AC-15), anti-talin mAb (8d4), antivinculin mAb ) and anti-a-tubulin mAb (DM 1A). Anti-Fak mAb and anti-tensin mAb were from UBI (Lake Placid, NY). Anti-human Cyclin B1 mAb (14541A), anti-integrin b1 Ab and anti-GFP Ab were purchased from Pharmingen (San Diego, CA), Chemicon International (Temecula CA) and Clonetech (Palo Alto, CA), respectively. Two dierent clones of anti-paxillin mAbs, clone Z035 and clone P13520, were from Zymed (San Francisco, CA) and Transduction Laboratories (Lexington, KY), respectively. Polyclonal anti-paxillin Ab was raised against a peptide derived from the human-paxillin amino acid sequence (aa 199 ± 217), which recognizes both a and b isoforms of paxillin (Mazaki et al., 1997) .
Cells
HeLa and Cos 7 cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% fetal calf serum (Gibco BRL, Gaithersburg, MD). 3Y1 and NIH3T3 cells were maintained with DMEM containing 5% fetal calf serum. CHO cells were maintained in Ham's F-12 with 10% fetal calf serum. Jurkat cells were maintained in RPMI 1640 with 10% FCS.
To collect mitotic cells from HeLa, CHO, 3Y1, NIH3T3 and Cos 7 cells, 40 ng/ml of nocodazole was added to the medium, and 12 ± 16 h later, round mitotic cells were harvested by gently shaking. For Jurkat cells, 400 ng/ml of nocodazole was applied for 24 h. Mitotic HeLa cells were also collected from synchronized populations using double thymidine block and release. Brie¯y, HeLa cells were ®rst arrested at G1/S by incubating cells with 2 mM thymidine (Sigma) for 17 h. Cells were then washed in warm medium and replated for 9 h, followed by another 17 h treatment with thymidine. Finally, HeLa cells were washed extensively and round mitotic cells were collected 3, 4 and 5 h later. More than 80% of cells collected were in mitotic-phase as assessed by staining with propidium iodide and analysis using¯ow cytometry (Ortho Diagnostis; Tokyo, Japan). Those cells treated with nocodazole, but remaining adherent to culture dishes, were used as nocodazole-treated interphase cells. Cell cycle distributions of the drug-treated interphase cells were also con®rmed using¯ow-cytometry. Cells were released from nocodazole-arrest by washing in pre-warmed medium and plating on rat ®bronectin-coated dishes (10 mg/ml; Gibco BRL). Under these conditions, most cells exited the mitosis within 1 ± 2 h.
The apparent half-lives of proteins were measured by treating nocodazole-arrested mitotic cells or cells at exponential growing phase with 100 mg/ml of cyclohexamide (Sigma). To block the cellular proteolytic degradation activities, 10 mM MG132 (a gift from MyoGenics, Cambridge, MA) was added together with cychroxamide.
To express each isoform of paxillin exogenously, NIH3T3 cells were infected with BOSC23 derived recombinant retroviruses bearing each paxillin coding sequence and selected in the presence of 2 mg/ml of puromycine for 1 week (Mazaki et al., 1997) . The construction of the retrovirus vector bearing GFP-fused paxillin cDNA or GFP cDNA will be published elsewhere. Exogenous expression of cDNA in Cos 7 cells were done using a DEAE-dextran method as described previously (Sabe et al., 1992) .
Immunoprecipitation and immunoblotting
Cell lysates were prepared with RIPA buer (1% Nonidet P-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 20 mM Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM EDTA, 50 mM NaF, 1 mM Na 3 VO 4 , 10 mM Na 2 MoO 4 , 1 mM phenyl methylsulfonyl¯uoride (Sigma), 20 mg/ml aprotinin (Sigma), 2 mg/ml leupeptin (Sigma), 3 mg/ml pepstatin A (Sigma)) unless otherwise described. Total cell lysates (20 mg of protein unless otherwise described) or paxillin immunoprecipitated from 200 mg of lysate proteins with an anti-paxillin monoclonal antibody (Transduction Laboratories) coupled with Protein GSepharose beads (Pharmacia LKB Biotechnology, Piscat-away, NJ) were then separated on SDS ± PAGE (8%), transfered to Immobilon P membrane ®lter (Millipore, Bedford MA) and subjected to immunoblotting analysis as described previously . Filters were then incubated with appropriate antibodies, and after washing, antibodies retained on ®lters were detected by enhanced chemiluminescence (ECL; Amersham, Arlington, IL) using horse radish peroxidase-conjugated anity-puri®ed antimouse IgG or anti-rabbit IgG antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA). For paxillin immunoblotting, results with its polyclonal antibody were shown in ®gures unless otherwise described. Protein concentration was determined by Dc protein assay kit (Bio-Rad Lab., Hercules, CA) using bovine serum albumin (Sigma) as a standard. Prestained rainbow marker (Amersham) was used as size-standard.
Phosphatase treatment and phosphoamino acid analysis
Total cell lysates (20 mg) made in a hypotonic buer (10 mM HEPES (pH 7.9), 10 mM KCl, 0.2 mM EDTA, 0.1 mM EGTA and 1 mM DTT were diluted tenfold in a buer containing 10 mM Tris-HCl (pH 8.0), 1 mM MgCl 2 , 1 mM phenyl methylsulfonyl¯uoride, 2 mg/ml leupeptin and % aprotinin), and treated with recombinant BAP (1 unit in 50 ml of reaction mixture) (Takara Shuzo Co., Otsu, Japan) for 1 h at 378C.
For the phosphoamino acid analysis, 2610 6 cells were incubated with phosphate-free DMEM (Gibco BRL) in the presence of 5% dialyzed fetal calf serum for 30 min, washed three times with phosphate-free DMEM, and then radiolabeled with 1 mCi/ml 32 P-orthophosphate (carrier free, Amersham) for 2 h with the same medium in the presence of 5% dialyzed fetal calf serum. Cell lysates were then made in RIPA buer, and paxillin was immunoprecipitated and separated on SDS ± PAGE. After excision of the radiolabeled band from the gel, phosphoamino acid analysis was done by hydrolyzing radiolabeled phosphopeptide with 6 N HCl for 90 min at 1058C, then separated on cellulose thin-layer plates electrophoresis with pH 3.5 buer (10 : 1 : 189 mixture of glacial acetic acid, pridine and water) at 1000 V for 60 min as described (Boyle et al., 1991) after being mixed with phosphoamino acid standards (Sigma). 32 P-labeled phosphoamino acids were then identi®ed by autoradiography and phosphoamino acid standards were identi®ed by spraying the plate with ninhydrin as described (Boyle et al., 1991) .
RNA blotting analysis
The full-length human paxillin coding region was isolated from U937 cDNA (Mazaki et al., 1997) . The fragment of human paxillin cDNA encompassing nucleotides 188 ± 1072 was used as a probe in Northern hybridization. RNA was prepared from nocodazole-arrested mitotic cells or exponential growing cells using the micro-scale RNA isolation kit (Clontech, Palo Alto, CA). Blotting and hybridizations were carried out according to standard protocols (Sambrooke et al., 1989) .
